

LIST OF FIGURES

Figure	Page
LITERATURE REVIEW	
1.	Malaria parasite life cycle. 9
2.	<i>Artemisia annua</i> . 13
3.	Artemisinin and its derivatives: artemisinin. (R=O), dihydroartemisinin (R=H), artemether (R=CH ₃), arteether (R=CH ₂ CH ₃), and artesunate (R=CO(CH ₂) ₂ CO ₂ Na). 13
CLINICAL EFFICACY OF MONOTHERAPY OF HIGH DOSE DIHYDROARTEMISININ OR COMBINATION THERAPY OF HIGH DOSE DIHYDROARTEMISININ AND MEFLOROQUINE IN VIETNAMESE PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA	
4.	Radical cure rates of two regimens, 5-day DHA monotherapy and DHA-MQ combination therapy, in uncomplicated falciparum malaria. The radical cure rate of DHA-MQ combination regimen is significantly higher than that of 5-day DHA regimen ($p = 0.003$). 56
PHARMACOKINETICS OF MEFLOROQUINE WITH DIHYDROARTEMISININ AS 2-DAY REGIMENS IN PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA	
5.	The parasitemia vs time (A) and the parasite clearance time (B) profiles following drug administration. 62

LIST OF FIGURES (cont.)

Figure		Page
6.	Median whole blood concentrations of MQ given at 6 (●: n=5) and 24 h (□: n=6) after an oral dose of DHA in male Vietnamese patients with acute uncomplicated falciparum malaria. Concentration-time profiles were best fitted with a two-compartment open model with first-order absorption and elimination with absorption lag time.	64
DEVELOPMENT AND VALIDATION OF A LIQUID CHROMATOGRAPHY – MASS SPECTROMETRY METHOD FOR THE SIMULTANEOUS QUANTIFICATION OF ARTESUNATE AND DIHYDROARTEMISININ IN HUMAN PLASMA		
7.	Chemical structures of (a) artemisinin (ARN), (b) dihydroartemisinin (DHA), and (c) artesunate (ARS).	83
8.	Chromatogram (a) and mass spectra (b, c, d) of ARS, DHA, and ARN.	83
9.	Chromatograms of ARS-LOD (a) and ARS-LOQ (b).	84
10.	Chromatograms of DHA-LOD (a) and DHA-LOQ (b).	84
11.	ARS calibration curve (n = 5) with nine concentrations from 10 to 3200 ng/ml; data are presented as mean ± SD.	84
12.	DHA calibration curve (n = 5) with nine concentrations from 10 to 3200 ng/ml; data are presented as mean ± SD.	84
13.	Plasma concentration-time profile of ARS over five days.	88
14.	Plasma concentration-time profile of DHA over five days.	88
15.	Plasma concentration-time profiles of ARS and DHA on day 1.	89

LIST OF FIGURES (cont.)

Figure	Page
PHARMACOKINETICS OF A FIVE-DAY ORAL DIHYDROARTEMISININ MONOTHERAPY REGIMEN IN PATIENTS WITH UNCOMPLICATED FALCIPARUM MALARIA	
16.	Chromatogram of DHA and ARN (A) and full scan mass spectra of DHA (B) and ARN (C). 96
17.	Limit of quantification of DHA in spiked plasma (10 ng/ml). 97
18.	DHA calibration curve (100 - 3,200 ng/ml). 97
19.	Parasite clearance curve after treatment. 99
20.	Fever clearance curve after treatment. 99
21.	DHA concentrations over 5 days at 1, 2, and 6 h after drug administration. Figure A shows no difference in DHA concentrations between d0 and d1. Figure B shows difference in DHA concentrations only at 6 h of d2 and d3 vs d4. Figure C shows difference in DHA concentrations at 6 h between d4 and other days. Data are presented as median (25 – 75 percentiles). 103
22.	DHA concentrations at 1h (A), 2 h (B), and 6 h (C) after drug administration over 5 days. The difference in DHA concentrations was found at 6 h on day 4 compared to those on days 0, 1, 2, and 3. Data are presented as mean \pm SD 106

LIST OF FIGURES (cont.)

Figure		Page
23.	<p>Observed DHA concentrations and fitting curves on day 0 and day 4. Figure A shows the comparison of DHA concentrations between 300-mg dose on day 0 and 100-mg dose on day 4. Figure B shows the comparison of DHA concentrations between day 0 and day 4 with the same 100-mg dose. There was significant difference in DHA concentrations between day 0 and day 4. Data are presented as median (25-75 percentiles).</p>	107
<p>ABSENCE OF TIME DEPENDENCY IN ARTESUNATE PHARMACOKINETICS IN HEALTHY SUBJECTS FOLLOWING A FIVE- DAY ORAL ADMINISTRATION</p>		
24.	<p>Plasma concentration-time profile of DHA in healthy volunteers following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days. Plot data are presented as median with 25–75 percentiles (●) and mean ± SD (●).</p>	116
25.	<p>Plasma concentration-time profile of DHA in healthy volunteers following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days. Plot data, (●) for day 1 and (■) for day 5, are presented as median (25–75 percentiles).</p>	118
26.	<p>Plasma concentration-time profile of ARS in healthy volunteers following the administration of 200 mg oral doses of ARS once daily over 5 consecutive days. Plot data are presented as median with 25–75 percentiles (●) and mean ± SD (●).</p>	120

LIST OF FIGURES (cont.)

Figure		Page
27.	Plasma concentration-time profile of ARS in healthy volunteers following the administration of 200 mg oral doses of ARS once daily for 5 consecutive days. Plot data, (●) for day 1 and (■) for day 5, are presented as median (25–75 percentiles).	121

สำนักหอสมุด